BRPI0922800A2 - anticorpos c-met - Google Patents

anticorpos c-met

Info

Publication number: BRPI0922800A2
Authority: BR; Brazil
Prior art keywords: met antibodies; antibodies; met
Prior art date: 2008-11-21

Application number

BRPI0922800A

Other languages

English (en)

Portuguese (pt)

Inventor

Jirong Lu

Julian Davies

Ling Liu

Mark Andrew Wortinger

Peter Edward Vaillancourt

Wei Zeng

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-21

Filing date

2009-11-18

Publication date

2015-12-22

2009-11-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2015-12-22 Publication of BRPI0922800A2 publication Critical patent/BRPI0922800A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BRPI0922800A 2008-11-21 2009-11-18 anticorpos c-met BRPI0922800A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11682508P	2008-11-21	2008-11-21
US21990309P	2009-06-24	2009-06-24
PCT/US2009/064881 WO2010059654A1 (en)	2008-11-21	2009-11-18	c-MET ANTIBODIES

Publications (1)

Publication Number	Publication Date
BRPI0922800A2 true BRPI0922800A2 (pt)	2015-12-22

Family

ID=41435259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922800A BRPI0922800A2 (pt)	2008-11-21	2009-11-18	anticorpos c-met

Country Status (27)

Country	Link
US (2)	US8217148B2 (es)
EP (2)	EP2358755B1 (es)
JP (1)	JP5688027B2 (es)
KR (1)	KR101334450B1 (es)
CN (1)	CN102216333B (es)
AR (1)	AR074360A1 (es)
AU (1)	AU2009316742B2 (es)
BR (1)	BRPI0922800A2 (es)
CA (1)	CA2743508C (es)
CY (1)	CY1116886T1 (es)
DK (1)	DK2358755T3 (es)
EA (1)	EA020398B1 (es)
ES (2)	ES2549760T3 (es)
HR (1)	HRP20151019T1 (es)
HU (1)	HUE026058T2 (es)
IL (1)	IL212633A (es)
JO (1)	JO3097B1 (es)
MX (1)	MX2011005400A (es)
NZ (1)	NZ592215A (es)
PA (1)	PA8849001A1 (es)
PL (1)	PL2358755T3 (es)
PT (1)	PT2358755E (es)
SI (1)	SI2358755T1 (es)
TR (1)	TR201802841T4 (es)
TW (1)	TWI477284B (es)
WO (1)	WO2010059654A1 (es)
ZA (1)	ZA201103586B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8849001A1 (es)	2008-11-21	2010-06-28	Lilly Co Eli	Anticuerpos de c-met
JP6055312B2 (ja)	2010-03-10	2017-01-11	ゲンマブエー／エス	Ｃ−ｍｅｔに対するモノクローナル抗体
JP2013534515A (ja) *	2010-06-01	2013-09-05	モナシュユニバーシティ	プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
JP2013537966A (ja)	2010-08-31	2013-10-07	ジェネンテック，インコーポレイテッド	バイオマーカー及び治療の方法
SG188324A1 (en)	2010-09-03	2013-04-30	Academia Sinica	Anti-c-met antibody and methods of use thereof
US8637027B2 (en) *	2010-11-03	2014-01-28	Argen-X B.V.	Anti c-Met antibodies
CN102276726B (zh) *	2011-03-16	2014-02-19	常州新泉生物医药科技有限公司	肝细胞生长因子受体活性基团的融合蛋白
WO2012174529A2 (en) *	2011-06-17	2012-12-20	Indiana University Research And Technology Corporation	Methods for increasing the potency and efficacy of stem cells
KR20140064971A (ko)	2011-09-19	2014-05-28	제넨테크, 인크.	c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
EP2758430A4 (en) *	2011-09-20	2015-06-03	Lilly Co Eli	ANTI-C-MET ANTIBODY
KR101865223B1 (ko) *	2011-10-05	2018-06-08	삼성전자주식회사	항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130037153A (ko) *	2011-10-05	2013-04-15	삼성전자주식회사	항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko)	2011-10-05	2013-04-15	삼성전자주식회사	ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (en)	2011-11-03	2013-05-10	Argen-X B.V.	Chimeric polypeptides and methods of use
WO2013078170A1 (en)	2011-11-21	2013-05-30	Genentech, Inc.	Purification of anti-c-met antibodies
US20150147274A1 (en)	2011-12-02	2015-05-28	Cancer Research Technology Limited	Antibodies against hgf - receptor and uses
CN104334581B (zh) *	2012-05-09	2018-02-02	伊莱利利公司	抗‑c‑Met抗体
JP6429771B2 (ja) *	2012-06-21	2018-11-28	ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ｃ−Ｍｅｔに結合する抗原結合タンパク質
US9931400B2 (en)	2012-09-12	2018-04-03	Samsung Electronics Co., Ltd.	Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
EP2839860B1 (en)	2012-10-12	2019-05-01	MedImmune Limited	Pyrrolobenzodiazepines and conjugates thereof
HK1211235A1 (en)	2013-02-22	2016-05-20	霍夫曼-拉罗奇有限公司	Methods of treating cancer and preventing drug resistance
JP6444902B2 (ja)	2013-03-13	2018-12-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びその結合体
KR102049990B1 (ko) *	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102042174B1 (ko) *	2013-03-29	2019-11-08	삼성전자주식회사	인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
EP2992019B1 (en)	2013-04-30	2019-03-06	Agency For Science, Technology And Research	Mab 2 anti-met antibody
CN105745335A (zh) *	2013-08-14	2016-07-06	佳根曼斯菲尔德有限公司	用于对cMET核酸进行多模态分析的组合物及方法
BR112016008125B1 (pt)	2013-10-14	2023-11-21	Janssen Biotech, Inc.	Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
US9717715B2 (en)	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh) *	2013-12-23	2016-03-16	美國禮來大藥廠	結合ｅｇｆｒ及ｍｅｔ之多功能抗體
TW201622744A (zh) *	2014-03-04	2016-07-01	美國禮來大藥廠	癌症之組合療法
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CA2944717A1 (en)	2014-05-23	2015-11-26	Genentech, Inc.	Mit biomarkers and methods using the same
JP6531166B2 (ja)	2014-09-10	2019-06-12	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びそのコンジュゲート
AU2015316522B2 (en) *	2014-09-16	2021-01-21	Symphogen A/S	Anti-met antibodies and compositions
JP6864953B2 (ja)	2014-12-09	2021-04-28	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN107613974B (zh) *	2015-03-16	2021-01-15	塞尔德克斯医疗公司	抗-met抗体及其使用方法
US10344071B2 (en)	2015-07-28	2019-07-09	Musc Foundation For Research Development	Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
JP2019500011A (ja)	2015-11-03	2019-01-10	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
CN106810611A (zh) *	2015-11-30	2017-06-09	中国科学院深圳先进技术研究院	抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
JP6669882B2 (ja)	2016-02-05	2020-03-18	ヘリックスミスカンパニーリミテッド	抗−ｃ−ＭＥＴ抗体及びその用途
GB2551372A (en) *	2016-06-16	2017-12-20	Bombardier Primove Gmbh	A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer
SG11201811062XA (en)	2016-06-21	2019-01-30	Janssen Biotech Inc	Cysteine engineered fibronectin type iii domain binding molecules
CN107556386A (zh) *	2016-06-30	2018-01-09	中国科学院深圳先进技术研究院	抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
CN107556387A (zh) *	2016-06-30	2018-01-09	中国科学院深圳先进技术研究院	抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556388A (zh) *	2016-06-30	2018-01-09	中国科学院深圳先进技术研究院	抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
CN107573416A (zh) *	2016-06-30	2018-01-12	中国科学院深圳先进技术研究院	抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
US20190270796A1 (en) *	2016-07-26	2019-09-05	Nihon University	Therapeutic agent for periodontitis and compostion for treating periodontitis
US10439449B2 (en)	2016-08-10	2019-10-08	Microsoft Technology Licensing, Llc	Coupling device modules for inductive data transmission
CA3036643C (en)	2016-09-29	2021-10-26	Mitsubishi Tanabe Pharma Corporation	Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
CN109862919A (zh)	2016-10-11	2019-06-07	免疫医疗有限公司	抗体-药物缀合物联合免疫介导的治疗剂
WO2018071500A1 (en)	2016-10-11	2018-04-19	Agenus Inc.	Anti-lag-3 antibodies and methods of use thereof
TWI782930B (zh) *	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20210283249A1 (en)	2016-11-16	2021-09-16	Eli Lilly And Company	Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
US11167039B2 (en)	2016-11-23	2021-11-09	Eli Lilly And Company	MET antibody drug conjugates
US10611823B2 (en)	2016-12-14	2020-04-07	Hanssen Biotech, Inc	CD137 binding fibronectin type III domains
BR112019012154A2 (pt)	2016-12-14	2019-11-12	Janssen Biotech Inc	domínios do tipo iii da fibronectina de ligação a cd8a
WO2018111976A1 (en)	2016-12-14	2018-06-21	Janssen Biotech, Inc.	Pd-l1 binding fibronectin type iii domains
WO2018129029A1 (en) *	2017-01-04	2018-07-12	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
CN106986932A (zh) *	2017-04-06	2017-07-28	海口市人民医院	一种c‑Met表位肽及其应用
US11479612B2 (en) *	2017-05-30	2022-10-25	Chong Kun Dang Pharmaceutical Corp.	Anti-c-Met antibody and use thereof
CN109771642B (zh) *	2017-11-13	2022-09-20	同济大学苏州研究院	c-MET激动型抗体及其用途
GB201803892D0 (en)	2018-03-12	2018-04-25	Ultrahuman Six Ltd	C-met binding agents
KR20210016562A (ko)	2018-05-23	2021-02-16	에이디씨 테라퓨틱스 에스에이	분자 애쥬번트
US11896682B2 (en)	2019-09-16	2024-02-13	Regeneron Pharmaceuticals, Inc.	Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
EP4045061A4 (en)	2019-10-14	2024-04-17	ARO Biotherapeutics Company	FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
US12491255B2 (en)	2019-10-14	2025-12-09	Aro Biotherapeutics Company	EPCAM binding fibronectin type III domains
WO2021076574A2 (en)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Fn3 domain-sirna conjugates and uses thereof
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
RS66266B1 (sr) *	2021-02-03	2024-12-31	Mythic Therapeutics Inc	Anti-met antitela i njihova primena
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
AU2022254291A1 (en)	2021-04-08	2023-10-12	Byondis B.V.	Anti-c-met antibodies and antibody-drug conjugates
JP2024517610A (ja)	2021-04-14	2024-04-23	アロ・バイオセラピューティクス・カンパニー	Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
EP4323008A1 (en)	2021-04-14	2024-02-21	ARO Biotherapeutics Company	Fn3 domain-sirna conjugates and uses thereof
CN113788895B (zh) *	2021-10-14	2023-09-15	陕西健吉跃生物科技有限公司	一种兔多克隆抗体及其制备方法和应用
JP2024541058A (ja)	2021-11-03	2024-11-06	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．	抗体の特異的共役
TW202500584A (zh)	2023-05-19	2025-01-01	法商施維雅藥廠	抗met抗體、抗體-藥物結合物、組合物及其用途
WO2025025434A1 (zh) *	2023-08-02	2025-02-06	百泰生物药业有限公司	EGFR/c-Met双特异性抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1992020792A1 (en)	1991-05-10	1992-11-26	Farmitalia Carlo Erba S.R.L.	Truncated forms of the hepatocyte growth factor (hgf) receptor
US5686292A (en)	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en)	1995-06-02	2001-04-10	Genetech, Inc.	Hepatocyte growth factor receptor antagonists and uses thereof
WO2000064946A2 (en)	1999-04-28	2000-11-02	Board Of Regents, The University Of Texas System	Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2004072117A2 (en)	2003-02-13	2004-08-26	Pharmacia Corporation	Antibodies to c-met for the treatment of cancers
US20040208876A1 (en)	2003-04-18	2004-10-21	Kim Kyung Jin	Monoclonal antibodies to hepatocyte growth factor
ITMI20031127A1 (it)	2003-06-05	2004-12-06	Uni Degli Studi Del Piemont E Orientale Am	Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) *	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) *	2003-11-11	2006-03-10	국립암센터	Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005058965A1 (en)	2003-12-11	2005-06-30	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
AU2004309347B2 (en)	2003-12-19	2010-03-04	Genentech, Inc.	Monovalent antibody fragments useful as therapeutics
PT1773885E (pt)	2004-08-05	2010-07-21	Genentech Inc	Antagonistas anti-cmet humanizados
US7615529B2 (en)	2005-03-25	2009-11-10	Genentech, Inc.	Methods and compositions for modulating hyperstabilized c-met
BRPI0707480A8 (pt)	2006-02-06	2022-11-08	Vertical Bio Ag	Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos
EP1991585A2 (en) *	2006-02-22	2008-11-19	Eli Lilly And Company	Humanized anti-ghrelin antibodies
JP5536445B2 (ja)	2006-03-30	2014-07-02	ノバルティスアーゲー	ｃ−Ｍｅｔの抗体の組成物およびその使用方法
KR100829972B1 (ko)	2006-07-14	2008-05-16	재단법인서울대학교산학협력재단	항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
EP1914242A1 (en) *	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
ES2392637T3 (es) *	2007-02-08	2012-12-12	The Regents Of The University Of California	Mutaciones de Gnaq en el melanoma
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
PA8849001A1 (es)	2008-11-21	2010-06-28	Lilly Co Eli	Anticuerpos de c-met

2009
- 2009-11-13 PA PA20098849001A patent/PA8849001A1/es unknown
- 2009-11-15 JO JOP/2009/0424A patent/JO3097B1/ar active
- 2009-11-16 AR ARP090104438A patent/AR074360A1/es unknown
- 2009-11-17 TW TW098139025A patent/TWI477284B/zh not_active IP Right Cessation
- 2009-11-18 MX MX2011005400A patent/MX2011005400A/es active IP Right Grant
- 2009-11-18 WO PCT/US2009/064881 patent/WO2010059654A1/en not_active Ceased
- 2009-11-18 HU HUE09752708A patent/HUE026058T2/en unknown
- 2009-11-18 SI SI200931262T patent/SI2358755T1/sl unknown
- 2009-11-18 ES ES09752708.9T patent/ES2549760T3/es active Active
- 2009-11-18 EA EA201170716A patent/EA020398B1/ru not_active IP Right Cessation
- 2009-11-18 PT PT97527089T patent/PT2358755E/pt unknown
- 2009-11-18 JP JP2011537557A patent/JP5688027B2/ja active Active
- 2009-11-18 EP EP09752708.9A patent/EP2358755B1/en active Active
- 2009-11-18 CN CN200980146173.1A patent/CN102216333B/zh active Active
- 2009-11-18 US US12/620,617 patent/US8217148B2/en active Active
- 2009-11-18 DK DK09752708.9T patent/DK2358755T3/en active
- 2009-11-18 CA CA2743508A patent/CA2743508C/en not_active Expired - Fee Related
- 2009-11-18 HR HRP20151019TT patent/HRP20151019T1/hr unknown
- 2009-11-18 EP EP15175051.0A patent/EP2963058B1/en active Active
- 2009-11-18 TR TR2018/02841T patent/TR201802841T4/tr unknown
- 2009-11-18 KR KR1020117011522A patent/KR101334450B1/ko not_active Expired - Fee Related
- 2009-11-18 AU AU2009316742A patent/AU2009316742B2/en not_active Ceased
- 2009-11-18 ES ES15175051.0T patent/ES2663825T3/es active Active
- 2009-11-18 PL PL09752708T patent/PL2358755T3/pl unknown
- 2009-11-18 BR BRPI0922800A patent/BRPI0922800A2/pt not_active IP Right Cessation
- 2009-11-18 NZ NZ592215A patent/NZ592215A/xx not_active IP Right Cessation
2011
- 2011-05-02 IL IL212633A patent/IL212633A/en not_active IP Right Cessation
- 2011-05-16 ZA ZA2011/03586A patent/ZA201103586B/en unknown
2012
- 2012-06-25 US US13/531,858 patent/US8398974B2/en active Active
2015
- 2015-10-02 CY CY20151100880T patent/CY1116886T1/el unknown

Also Published As

Publication number	Publication date
CN102216333B (zh)	2014-05-21
US20120263723A1 (en)	2012-10-18
CA2743508C (en)	2016-07-19
KR20110074612A (ko)	2011-06-30
EP2963058B1 (en)	2018-02-21
AU2009316742A1 (en)	2010-05-27
KR101334450B1 (ko)	2013-12-02
HUE026058T2 (en)	2016-05-30
EP2358755B1 (en)	2015-09-02
JP5688027B2 (ja)	2015-03-25
MX2011005400A (es)	2011-06-20
EP2963058A1 (en)	2016-01-06
NZ592215A (en)	2012-09-28
TWI477284B (zh)	2015-03-21
AR074360A1 (es)	2011-01-12
DK2358755T3 (en)	2015-11-16
PA8849001A1 (es)	2010-06-28
US8398974B2 (en)	2013-03-19
ES2663825T3 (es)	2018-04-17
HK1158229A1 (en)	2012-07-13
ZA201103586B (en)	2013-10-30
ES2549760T3 (es)	2015-11-02
EP2358755A1 (en)	2011-08-24
PT2358755E (pt)	2015-11-12
US8217148B2 (en)	2012-07-10
IL212633A0 (en)	2011-07-31
AU2009316742B2 (en)	2012-06-07
TW201023885A (en)	2010-07-01
TR201802841T4 (tr)	2018-03-21
PL2358755T3 (pl)	2016-01-29
EA020398B1 (ru)	2014-10-30
EA201170716A1 (ru)	2011-12-30
JO3097B1 (ar)	2017-03-15
CN102216333A (zh)	2011-10-12
SI2358755T1 (sl)	2015-10-30
CA2743508A1 (en)	2010-05-27
JP2012509881A (ja)	2012-04-26
WO2010059654A1 (en)	2010-05-27
IL212633A (en)	2015-03-31
HRP20151019T1 (hr)	2015-10-23
CY1116886T1 (el)	2017-04-05
US20100129369A1 (en)	2010-05-27

Publication	Publication Date	Title
BRPI0922800A2 (pt)	2015-12-22	anticorpos c-met
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
BRPI0917148A2 (pt)	2015-12-01	anticorpos anti-cd5
BRPI0912173A2 (pt)	2016-07-26	anticorpos anti-flt3
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
DE602009000234D1 (de)	2010-11-11	msignals
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
DE602009000862D1 (de)	2011-04-28	Gehwagenbremse
DE112009001946A5 (de)	2011-07-14	Mobelauszugsführung
DE602009000488D1 (de)	2011-02-10	Obstvereinzelvorrichtung
BRPI0907863A2 (pt)	2019-09-24	pirrolopirimidinacarboxamidas

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-23	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2019-02-12	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.